METRNL and myeloid sarcoma: The present research introduces novel insights regarding the involvement of specific biomarkers, including FGF-21, Metrnl, sortilin, and nesfatin-1, in the development of major disorders associated with metabolic syndrome (MS) and their potential utility as prognostic indicators for diagnosing these conditions.